Parkin Antikörper (C-Term)

Produktnummer ABIN350726

Der Kaninchen Polyklonal Anti-Parkin-Antikörper wurde für WB und IHC validiert. Er ist geeignet, Parkin in Proben von Maus und Ratte zu detektieren.

Kurzübersicht für Parkin Antikörper (C-Term) (ABIN350726)

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Reaktivität: Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Parkin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Produktdetails anti-Parkin Antikörper

Bindungsspezifität: C-Term

Verwendungszweck: Rabbit antibody to Parkin

Spezifität: Specific for Parkin.

Kreuzreaktivität: Human, Maus, Ratte

Kreuzreaktivität (Details): Other species not yet tested.

Aufreinigung: IgG

Immunogen: A synthetic peptide from the c-terminal of Parkin (PARK2 Parkinson disease protein 2) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in rat and shares 95% identity with mouse sequence.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC WB. A concentration of 10-50,micro,g,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstitute in 500 µl of sterile water. Centrifuge to remove any insoluble material.

Handhabung: Avoid freeze and thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Haltbarkeit: 12 months

Details zu Parkin

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Andere Bezeichnung: Parkin

Hintergrund: Function: Functions within a multiprotein E3 ubiquitin ligase complex catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11 CCNE1 GPR37 STUB1 a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity proteasomal dysfunction GPR37 accumulation and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. Subcellular location: Cytoplasm. Nucleus. Note: Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Tissue specificity: Highly expressed in the brain including the substantia nigra. Expressed in heart testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.

Pathways: Autophagie, Ubiquitin Proteasome Pathway